Does EVOLOCUMAB Cause Stent placement? 244 Reports in FDA Database
Lower Your Cholesterol — The Natural Way
The Oxidized Cholesterol Strategy: a science-backed plan for heart health.
According to the FDA Adverse Event Reporting System (FAERS), 244 reports of Stent placement have been filed in association with EVOLOCUMAB (REPATHA). This represents 0.2% of all adverse event reports for EVOLOCUMAB.
244
Reports of Stent placement with EVOLOCUMAB
0.2%
of all EVOLOCUMAB reports
5
Deaths
87
Hospitalizations
How Dangerous Is Stent placement From EVOLOCUMAB?
Of the 244 reports, 5 (2.0%) resulted in death, 87 (35.7%) required hospitalization.
Is Stent placement Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for EVOLOCUMAB. However, 244 reports have been filed with the FAERS database.
What Other Side Effects Does EVOLOCUMAB Cause?
Device difficult to use (31,807)
Drug dose omission by device (23,957)
Wrong technique in product usage process (21,664)
Accidental exposure to product (16,160)
Injection site pain (9,988)
Product storage error (6,606)
Back pain (5,254)
Myalgia (5,061)
Drug dose omission (4,914)
Injection site bruising (4,409)
What Other Drugs Cause Stent placement?
RANOLAZINE (593)
ADALIMUMAB (227)
ROSIGLITAZONE (196)
ETANERCEPT (174)
CLOPIDOGREL BISULFATE (167)
RIVAROXABAN (122)
ASPIRIN (118)
APIXABAN (116)
MACITENTAN (108)
FLUTICASONE\SALMETEROL (105)
Which EVOLOCUMAB Alternatives Have Lower Stent placement Risk?
EVOLOCUMAB vs EXELON
EVOLOCUMAB vs EXEMESTANE
EVOLOCUMAB vs EXENATIDE
EVOLOCUMAB vs EXFORGE
EVOLOCUMAB vs EXJADE